Previous studies have shown that NSCLC patients with oncogenic driver mutations, such as sensitizing EGFR and ALK alterations, often see limited benefit from immunotherapy when used as a standalone treatment (22, 23, 43, 44). This evidence concerns the gene EGFR and non-small cell lung carcinoma.